Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR27 | Q9NS67 | 6/20 | 0.55 |
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | MARK3 | P27448 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003366 | 0.96 | GPR27 (0.55) | GPR27CDK2CSNK2A1CCNA2FLT3 | |
| SCHEMBL4014275 | 0.87 | NTRK1 (0.48) | CSNK2A1 | |
| SCHEMBL4010483 | 0.84 | CHEK2 (0.52) | JAK2JAK1AURKAAURKB | |
| SCHEMBL1461034 | 0.84 | MAPT (0.59) | CDK2CSNK2A1CCNA2FLT3CCNA1 | |
| SCHEMBL26715246 | 0.83 | ALDH1A1 (0.50) | — | |
| SCHEMBL4010147 | 0.83 | JAK2 (0.50) | CSNK2A1FLT3TP53ROCK1JAK2 | |
| SCHEMBL4008270 | 0.83 | MAPT (0.60) | GPR27CDK2CSNK2A1CCNA2FLT3 | |
| SCHEMBL4005840 | 0.82 | MAP2K4 (0.48) | CSNK2A1FLT3TP53 | |
| SCHEMBL4010178 | 0.82 | FLT3 (0.51) | CDK2CSNK2A1CCNA2FLT3CCNA1 | |
| SCHEMBL1461652 | 0.81 | MAP2K4 (0.60) | AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | GPR27 2427/4885CDK2 10/4885CSNK2A1 129/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | GPR27 2624/4885CDK2 28/4885CSNK2A1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.